IMAB Lemzoparlimab Phase 1 Clinical Trial Data Update Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the I-Mab Lemzoparlimab Phase I Clinical Trial Data Update Conference Call. (Operator Instructions)
Please note, this conference is being recorded today. I would now like to hand the conference over to the company's CFO. Please go ahead, sir.
Thank you, Rachel. Thank you. Hello, everyone. Good night, or good morning, depending on where you are. My name is Jielun Zhu, Chief Financial Officer of I-Mab. Thank you for your time joining this call. With me on the call today are Dr. Jingwu Zang, Founder and Honorary Chairman of I-Mab as well as Dr. Joan Shen, CEO of I-Mab.
We plan to go through a deep dive analysis of the preliminary clinical efficacy results of lemzoparlimab, also known as TJC4, from its U.S. Phase I clinical trial for the treatment of relapsed or refractory solid tumors. The results are being presented this week at the 2020 Society for Immunotherapy of Cancer, SITC, annual meeting held virtually. The purpose of this call is to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
